FDA Approved: TNKASE — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for TNKASE (tenecteplase) filed by Genentech, Inc., enabling changes to the product's labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• TNKASE (tenecteplase)

Snippet

SUPPL AP for TNKASE (TENECTEPLASE)